Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients

Bonaventura Clotet*, Jorge Carmena, Federico Pulido, Isabel Luque, Felipe Rodriguez-Alcántara, Jose Hernandez Quero, Hernando Knobel, José Lopez Aldeguer, José Antonio Maradona, Angeles Masabeu, Enric Pedrol, Joaquín Portilla, Esteban Ribera, Jesús Santos, María Jesús Téllez, Luis Trapiella, Carlos Alonso Villaverde

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

21 Citations (Scopus)

Abstract

Purpose: The main objective of the study was to evaluate patients' adherence to a fixed dose combination containing abacavir, zidovudine, and lamivudine (TZV) and to evaluate whether TZV might improve general satisfaction and quality of life (QOL) with anti-HIV treatment. Method: Patients with viral load (VL) <400 copies switched their antiretroviral therapy to TZV. Adherence was assessed by patient self-report and medication accountability at week 24. General satisfaction was evaluated with 10-point Visual Analog Scale (VAS) at baseline and week 24. QOL was assessed with MOS-HIV questionnaire at baseline and weeks 12 and 24. Biochemical and hematological parameters were evaluated for safety reasons. Results: A total of 224 patients were included in the study. Overall, 81% (intent to treat [ITT]) and 98% (per protocol [PP]) of patients reported an adherence >95%, reaching 75% and 100% among the intravenous drug user population by ITT and PP analysis, respectively. General satisfaction was significantly higher at week 24 (90 ± 14 vs. 53 ± 26) in both ITT and PP populations (p < .0001). There were no statistically significant differences in QOL. Total cholesterol and triglycerides levels decreased significantly at week 24 compared to baseline (p < .05). Conclusion: Patients who switched to TZV showed an increase in general satisfaction and high levels of adherence.

Original languageAmerican English
Pages (from-to)33-39
Number of pages7
JournalHIV Clinical Trials
Volume5
Issue number1
DOIs
Publication statusPublished - Jan 2004

Keywords

  • Abacavir
  • Adherence
  • General satisfaction
  • HIV
  • Lamivudine
  • Lipids
  • Quality of life
  • Zidovudine

Fingerprint Dive into the research topics of 'Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients'. Together they form a unique fingerprint.

Cite this